PPD, Inc. (PPD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PPD, Inc. (PPD) trades at $47.28. PPD, Inc. is a global contract research organization (CRO) providing drug development services to the biopharmaceutical industry. The company operates through two segments: Clinical Development Services and Laboratory Services. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PPD: PPD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PPD against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PPD: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →PPD, Inc. (PPD) Healthcare & Pipeline Overview
PPD, Inc. delivers comprehensive drug development solutions to pharmaceutical and biotech companies worldwide, focusing on clinical and laboratory services. With a global presence and a wide range of services, PPD supports clients from early development through post-approval stages, navigating the complexities of bringing new therapies to market.
What Is the Investment Thesis for PPD?
PPD, Inc. presents an investment case centered on its established position in the growing CRO market. The company's comprehensive service offerings, spanning clinical development and laboratory services, cater to the increasing demand from pharmaceutical and biotechnology companies seeking to outsource research and development activities. While PPD maintains a solid gross margin of 38.4%, its relatively high P/E ratio of 106.7 suggests a premium valuation. Growth catalysts include expanding partnerships with pharmaceutical companies and increasing demand for specialized laboratory services. Potential risks include intense competition in the CRO market and the impact of regulatory changes on drug development processes. Investors should monitor PPD's ability to maintain its market share and adapt to evolving industry trends.
Based on FMP financials and quantitative analysis
PPD Key Highlights
PPD operates in the Clinical Development Services and Laboratory Services segments, providing a comprehensive suite of services.
- The company serves pharmaceutical, biotechnology, medical device, and government organizations.
- PPD's gross margin stands at 38.4%, indicating a solid profitability level in its service offerings.
- The company's P/E ratio is 106.7, reflecting investor expectations of future growth.
- PPD was founded in 1985 and has grown into a global CRO with a significant presence in the biopharmaceutical industry.
Who Are PPD's Competitors?
PPD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABMD Abiomed, Inc. | $381.02 | +0.00% | $17.2B | 60 |
| BDX Becton, Dickinson and Company | $187.62 | +0.01% | $51.7B | 72 |
| CTLT Catalent, Inc. | $63.48 | +0.00% | $11.5B | 48 |
| DNA Ginkgo Bioworks Holdings, Inc. | $6.96 | -9.73% | $455M | — |
| ITCI ITCI | $131.87 | +0.00% | $14.1B | 63 |
| ZTS Zoetis Inc. | $75.44 | -1.62% | $31.6B | 85 |
| ESALF Eisai Co., Ltd. | $29.90 | +0.00% | $8.44B | 61 |
| LNTH Lantheus Holdings, Inc. | $100.24 | -0.24% | $6.53B | 88 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PPD's Key Strengths?
Comprehensive service offerings across clinical development and laboratory services.
- Established relationships with a diverse client base.
- Global presence and infrastructure.
- Expertise in navigating complex regulatory environments.
What Are PPD's Weaknesses?
High P/E ratio may indicate overvaluation.
- Reliance on the biopharmaceutical industry, making it susceptible to industry downturns.
- Intense competition in the CRO market.
- Profit margin of 3.3% is relatively low.
What Could Drive PPD Stock Higher?
PPD catalyst: Expansion of service offerings to include specialized areas such as personalized medicine and biomarker analysis.
- Strategic partnerships with pharmaceutical companies to secure long-term contracts and revenue streams.
- Geographic expansion into emerging markets to tap into new growth opportunities.
- Adoption of technology to improve clinical trial efficiency and reduce costs.
What Are the Key Risks for PPD?
Negative return on equity (-8.9%) — the business is not currently generating profit on shareholder capital.
- Rich valuation — a P/E of 106.7 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Insider selling — insiders were net sellers of roughly $2.7B recently.
- Regulatory changes impacting drug development processes and timelines.
- Economic downturns affecting R&D spending in the biopharmaceutical industry.
- Loss of key clients or contracts.
- Intense competition in the CRO market.
- Relatively low profit margin of 3.3%.
What Are the Growth Opportunities for PPD?
- Expansion of Laboratory Services: PPD can capitalize on the growing demand for specialized laboratory services, including bioanalytical testing, biomarker analysis, and vaccine development. The market for these services is expanding due to the increasing complexity of drug development and the need for more precise and personalized medicine. By investing in advanced technologies and expanding its laboratory infrastructure, PPD can attract new clients and increase its market share in this high-growth area. Timeline: Ongoing.
- Strategic Partnerships with Pharmaceutical Companies: PPD can strengthen its position in the CRO market by forming strategic partnerships with pharmaceutical companies. These partnerships can provide PPD with access to a steady stream of clinical trial projects and laboratory service contracts. By aligning its services with the specific needs of its pharmaceutical partners, PPD can enhance its value proposition and secure long-term revenue streams. Timeline: Ongoing.
- Geographic Expansion into Emerging Markets: PPD can expand its geographic reach by entering emerging markets, such as Asia-Pacific and Latin America. These markets offer significant growth opportunities due to their large populations, increasing healthcare spending, and growing demand for clinical research services. By establishing a presence in these regions, PPD can tap into new revenue streams and diversify its geographic footprint. Timeline: Ongoing.
- Adoption of Technology in Clinical Trials: PPD can leverage technology to improve the efficiency and effectiveness of its clinical trial services. This includes adopting electronic data capture (EDC) systems, remote patient monitoring devices, and data analytics tools. By embracing technology, PPD can reduce the cost and time associated with clinical trials, while also improving the quality of the data collected. Timeline: Ongoing.
- Focus on Personalized Medicine: PPD can capitalize on the growing trend towards personalized medicine by offering specialized services for the development of targeted therapies. This includes providing biomarker analysis, genetic testing, and patient stratification services. By focusing on personalized medicine, PPD can differentiate itself from its competitors and attract clients who are developing innovative therapies for specific patient populations. Timeline: Ongoing.
What Are PPD's Competitive Advantages?
- Established relationships with pharmaceutical and biotechnology companies.
- Comprehensive suite of services spanning clinical development and laboratory testing.
- Global reach and infrastructure.
- Expertise in navigating complex regulatory requirements.
What Does PPD Do?
Founded in 1985 and headquartered in Wilmington, North Carolina, PPD, Inc. has evolved into a leading global contract research organization (CRO). The company provides a comprehensive suite of drug development services to the biopharmaceutical industry, supporting clients from early-stage research through post-approval commercialization. PPD operates through two primary segments: Clinical Development Services and Laboratory Services. The Clinical Development Services segment offers a wide array of services, including product development consulting, early development support, Phase II-IV clinical trial management, accelerated enrollment strategies, peri- and post-approval services, and medical communications. The Laboratory Services segment provides bioanalytical, biomarker, vaccine science, good manufacturing practice (GMP), and central laboratory services. PPD serves a diverse clientele, including pharmaceutical, biotechnology, medical device, and government organizations, as well as other participants in the healthcare industry. The company's global reach and integrated service offerings position it as a strategic partner for organizations seeking to navigate the complexities of drug development and regulatory approval.
What Products and Services Does PPD Offer?
- Provides clinical development services to biopharmaceutical companies.
- Offers laboratory services including bioanalytical and biomarker analysis.
- Manages Phase II-IV clinical trials.
- Provides product development and consulting services.
- Offers accelerated enrollment strategies for clinical trials.
- Provides peri- and post-approval services for drugs.
- Offers medical communications services.
How Does PPD Make Money?
- Generates revenue by providing clinical development services to biopharmaceutical companies.
- Earns revenue through laboratory services, including bioanalytical and biomarker analysis.
- Contracts with pharmaceutical companies to manage clinical trials.
- Provides consulting services related to drug development.
What Industry Does PPD Operate In?
PPD, Inc. operates within the global contract research organization (CRO) market, which is experiencing steady growth driven by increasing R&D spending in the pharmaceutical and biotechnology industries. The market is characterized by intense competition among CROs offering a range of services, from clinical trial management to laboratory testing. Key trends include the growing adoption of technology in clinical trials, the increasing complexity of drug development, and the rising demand for specialized services such as biomarker analysis and vaccine development. PPD competes with other major CROs to secure contracts from pharmaceutical and biotech companies seeking to outsource their R&D activities.
Who Are PPD's Key Customers?
- Pharmaceutical companies
- Biotechnology companies
- Medical device companies
- Government organizations
Company Profile
PPD, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Wilmington, US. The company is led by CEO David S. Simmons. PPD has traded publicly since 2020.
Key Financial Metrics
Return on equity for PPD, Inc. stands at -8.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.4%, showing how much profit it generates from its asset base. PPD trades at a trailing price-to-earnings ratio of 106.65, above the Healthcare sector average of ~23x. A current ratio of 1.12 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.9%, the inverse of the P/E and a quick read on earnings relative to price.
Insider Activity
The most recent 12 insider filings for PPD, Inc. break down as 9 sales and 3 purchases. On net that is roughly 56.7M shares disposed (about $2.7B), a signal worth weighing alongside the fundamentals.
PPD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Community sentiment has shifted positively, with discussions highlighting PPD's strong pipeline and recent contract wins.
- Analysts point to the company's robust position in the life sciences sector, which is expected to grow as demand for clinical research increases.
- Recent strategic partnerships have enhanced PPD's market visibility, attracting more attention from investors.
Bear Case
- Concerns over regulatory changes in the life sciences sector have led to cautious sentiment among some investors, impacting stock perception.
- Negative community discussions have emerged regarding potential delays in project timelines, raising doubts about future revenue growth.
- Increased competition in the clinical research space could pressure PPD's market share, causing investors to reassess long-term prospects.
- Recent earnings reports have shown mixed results, leading to skepticism about the company's ability to meet growth expectations.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PPD Latest News
No recent news available for PPD.
PPD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PPD.
Price Targets
Wall Street price target analysis for PPD.
PPD MoonshotScore
What does this score mean?
The MoonshotScore rates PPD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David S. Simmons
Chief Executive Officer
David S. Simmons serves as the Chief Executive Officer of PPD, Inc., leading a global team of approximately 30,000 employees. His career spans various leadership roles within the pharmaceutical and healthcare industries. Prior to joining PPD, Simmons held executive positions at leading healthcare companies, demonstrating expertise in strategic planning, operational management, and business development. His experience includes driving growth initiatives, overseeing large-scale projects, and fostering collaborative partnerships.
Track Record: Under David S. Simmons' leadership, PPD has focused on expanding its service offerings and strengthening its global presence. Key achievements include strategic acquisitions, partnerships with leading pharmaceutical companies, and investments in innovative technologies. Simmons has also overseen efforts to improve operational efficiency and enhance the company's reputation as a trusted partner in drug development. He has successfully navigated the complexities of the CRO market, positioning PPD for continued growth and success.
Common Questions About PPD (Healthcare)
What does PPD, Inc. do?
PPD, Inc. is a global contract research organization (CRO) that provides comprehensive drug development services to the biopharmaceutical industry. The company operates through two segments: Clinical Development Services and Laboratory Services. PPD supports pharmaceutical, biotechnology, medical device, and government organizations by offering a wide range of services, from early-stage research and clinical trial management to post-approval commercialization support.
What do analysts say about PPD stock?
Analyst consensus on PPD stock reflects a generally positive outlook, driven by the company's strong position in the growing CRO market and its comprehensive service offerings. Key valuation metrics, such as the P/E ratio of 106.7, suggest that investors have high expectations for future growth.
What are the main risks for PPD?
PPD faces several key risks, including intense competition in the CRO market, which could put pressure on pricing and margins. Regulatory changes in the pharmaceutical industry could also impact the demand for PPD's services. Economic downturns could lead to reduced R&D spending by pharmaceutical and biotechnology companies, affecting PPD's revenue.
What are the key factors to evaluate for PPD?
Evaluate PPD on fundamentals, analyst consensus, and risk factors. P/E: 106.7x vs the S&P 500's ~20-25x. PPD, Inc. Not financial advice.
How frequently does PPD data refresh on this page?
PPD's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PPD's recent stock price performance?
PPD, Inc. (PPD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive service offerings across clinical development and laboratory services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PPD overvalued or undervalued right now?
PPD, Inc. (PPD) trades at 106.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PPD before investing?
Before investing in PPD, Inc. (PPD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.